throbber
[CANCER RESEARCH 59, 3581–3587, August 1, 1999]
`
`Advances in Brief
`
`Regulation of Cell Growth and Cyclin D1 Expression by the Constitutively Active
`FRAP-p70s6K Pathway in Human Pancreatic Cancer Cells1
`
`Martin Grewe, Frank Gansauge, Roland M. Schmid, Guido Adler, and Thomas Seufferlein2
`Departments of Internal Medicine I [M. G., R. M. S., G. A., T. S.] and Surgery [F. G.], University of Ulm, D-89081, Ulm, Germany
`
`include 59-terminal oligopyrimidine tract mRNA translation and pro-
`tein synthesis (11). The translation inhibitor 4E-BP1 is also phospho-
`rylated by the FRAP-p70s6K pathway. This leads to the dissociation of
`4E-BP1 from initiation factor eIF-4E, permitting increased protein
`translation and mitogenesis (12). In contrast, dephosphorylated 4E-
`BP1 interacts with eIF-4E and thereby inhibits cap structure-depen-
`dent protein synthesis and cell growth (13). Interestingly, rapamycin
`induces dephosphorylation of 4E-BP1,
`leading to inactivation of
`eIF-4E (6, 14). In contrast to previous studies, more recent reports
`suggest that 4E-BP1 is not a direct downstream target of p70s6K but
`is regulated by FRAP in a parallel manner (14). This view is supported
`by results obtained in p70s6K 2/2 cells, demonstrating that rapamy-
`cin can still prevent phosphorylation of 4E-BP1 and inhibit growth
`(15). Thus, rapamycin most likely inhibits growth via both p70s6K-
`dependent and -independent pathways. The role of these rapamycin-
`sensitive pathways in the growth of pancreatic cancer cells is un-
`known.
`In the present study, we demonstrate that the FRAP-p70s6K path-
`way is constitutively phosphorylated/active in MiaPaCa-2 and Panc-1
`human pancreatic cancer cell lines and a pancreatic cancer tissue
`sample. Rapamycin induced p70s6K dephosphorylation and inactiva-
`tion of constitutively active p70s6K in serum-starved MiaPaCa-2 and
`Panc-1 cells. Rapamycin also inhibited constitutive phosphorylation
`of the translation inhibitor 4E-BP1 in these cells. Furthermore, pro-
`liferation and colony formation of MiaPaCa-2 and Panc-1 human
`pancreatic cancer cells were markedly reduced in the presence of
`rapamycin. Finally, rapamycin profoundly inhibited expression of
`cyclin D1. Thus, our results suggest that the rapamycin-sensitive
`FRAP-p70s6K pathway could serve as a novel target for therapeutic
`intervention in pancreatic cancer.
`
`Materials and Methods
`
`Abstract
`
`The FRAP-p70s6K signaling pathway was found to be constitutively
`phosphorylated/active in MiaPaCa-2 and Panc-1 human pancreatic can-
`cer cells and a pancreatic cancer tissue sample as judged by the retarded
`electrophoretic mobility of the two major FRAP downstream targets,
`p70s6K and 4E-BP1. Treatment of cells with rapamycin, a selective FRAP
`inhibitor, inhibited basal p70s6K kinase activity and induced dephospho-
`rylation of p70s6K and 4E-BP1. Moreover, rapamycin inhibited DNA
`synthesis as well as anchorage-dependent and -independent proliferation
`in MiaPaCa-2 and Panc-1 cells. Finally, rapamycin strikingly inhibited
`cyclin D1 expression in pancreatic cancer cells. Thus, inhibitors of the
`constitutively active FRAP-p70s6K pathway may provide a novel thera-
`peutic approach for pancreatic cancer.
`
`Introduction
`
`Pancreatic cancer constitutes the fourth leading cause of cancer
`death in Western countries for both sexes and has a dismal prognosis
`(1). The growth of pancreatic cancer is driven by multiple factors such
`as activating mutations in the small GTPase Ki-ras and various
`growth factors acting in an autocrine or paracrine manner (2). How-
`ever, the downstream targets of these proteins and the arising signal
`transduction pathways involved in autocrine/paracrine human pancre-
`atic cancer cell growth are poorly understood. Defining these path-
`ways could give rise to novel therapeutic approaches that are urgently
`needed.
`The serine/threonine kinase p70s6K is a highly conserved element in
`a wide array of cellular processes including the mitogenic response to
`growth factors (3). This enzyme is activated in vivo by phosphoryla-
`tion mediated in part by a phosphatidyl kinase-related kinase, FRAP3
`or mTOR (mammalian target of rapamycin; Ref. 4). The immunosup-
`pressant rapamycin has emerged as a useful tool to elucidate the
`cellular function of FRAP and its downstream target, p70s6K (3, 5, 6):
`rapamycin inhibits FRAP by forming a stable complex with the
`immunophilin FK506-binding protein, which binds to FRAP. As a
`result of this interaction, rapamycin induces dephosphorylation of
`several sites (Thr229, Thr389, and Ser404) on p70s6K, leading to its
`rapid inactivation (7). Interestingly, rapamycin blocks the prolifera-
`tion of a variety of cells that have not entered the cell cycle (8, 9).
`Furthermore, we have recently shown that rapamycin inhibits consti-
`tutive p70s6K phosphorylation and cell growth in classical small cell
`lung cancer cell lines (10). Consequently, there has been considerable
`interest in the downstream targets of rapamycin and p70s6K that
`
`Cell Culture. Human pancreatic cancer cell lines MiaPaCa-2 and Panc-1
`were purchased from the American Type Culture Collection (Manassas, VA).
`Stocks were maintained in DMEM supplemented with 10% (v/v) FBS in a
`humidified atmosphere of 5% CO2: 95% air at 37°C. The cells were passaged
`every 3 days.
`Tissue Samples. Pancreatic carcinoma tissue samples were obtained from
`a patient undergoing a surgical operation for pancreatic cancer at the Depart-
`ment of General Surgery, University of Ulm. Informed consent was obtained
`from the patient before surgery. The tissue was collected after surgical re-
`moval, snap-frozen immediately in liquid nitrogen, and stored at 280°C.
`Immunoprecipitations and Western Blotting. MiaPaCa-2 and Panc-1
`cells were washed twice in serum-free DMEM and incubated in fresh DMEM
`for an additional 24 h. Cells were then treated with rapamycin as indicated in
`the figure legends and lysed in 50 mM Tris-HCl, 5 mM EDTA, 100 mM NaCl,
`40 mM b-glycerophosphate, 50 mM NaF, 1 mM Na3VO4, 1% Triton X-100, 1
`mM phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, and 10 mg/ml leupep-
`tin (pH 7.6; lysis buffer). For immunoprecipitations, lysates were incubated
`with a polyclonal anti-4E-BP1 antibody for 2 h at 4°C on a rotating wheel with
`protein A-Sepharose beads added for the second h. Beads were washed twice
`in lysis buffer and resuspended in 23 SDS-PAGE sample buffer. Proteins were
`further analyzed by SDS-PAGE, followed by Western blotting using a mono-
`ARGENTUM
`3581
`Exhibit 1014
`
`Received 3/12/99; accepted 6/16/99.
`The costs of publication of this article were defrayed in part by the payment of page
`charges. This article must therefore be hereby marked advertisement in accordance with
`18 U.S.C. Section 1734 solely to indicate this fact.
`1 Supported by a Grant SFB 518/B3 from the DFG (to T. S.).
`2 To whom requests for reprints should be addressed, at Department of Internal
`Medicine I, Medizinische Universita¨tsklinik Ulm, Robert-Koch Strasse 8, D-89081
`Ulm/Germany. Phone: 49-731-502-4307; Fax: 49-731-502-4302; E-mail:
`thomas.
`seufferlein@medizin.uni-ulm.de.
`3 The abbreviations used are: FRAP, FK506-binding protein rapamycin-associated
`protein; FBS, fetal bovine serum; TGF, transforming growth factor; ERK, extracellular
`signal-regulated kinase; BrdUrd, bromodeoxyuridine.
`
`
`
`Downloaded from on June 27, 2015. © 1999 American Association for Cancercancerres.aacrjournals.org
`
`
`Research.
`
`000001
`
`

`

`REGULATION OF CELL GROWTH AND CYCLIN D1 EXPRESSION
`
`Results
`
`from Upstate Biotechnology, Inc. The polyclonal anti-ERK2 antibody was a
`kind gift of Dr. Jo van Lint (Katholieke Universiteit, Leuven, Belgium). PD
`098059 was obtained from New England Biolabs. Protein A-Sepharose and the
`BrdUrd labeling and detection kit were from Boehringer Mannheim. Enhanced
`chemiluminescence reagents, [3H]thymidine, and [g-32P]ATP, were from Am-
`ersham. All other reagents were of the purest grade available.
`
`clonal anti-eIF-4E antibody or a polyclonal anti-4E-BP1 antibody with immu-
`noreactive bands visualized by enhanced chemiluminescence detection. For
`p70s6K2 and 4E-BP1 mobility shift assays and detection of cyclin D1, cyclin
`E, and p27kip1, cells were treated as indicated in the figure legends and lysed
`in SDS-PAGE sample buffer, and samples were further analyzed by SDS-
`PAGE and Western blotting with specific antisera to these proteins essentially
`as described above. Pancreatic tissues were lysed and dissociated by sonica-
`tion. The lysates were subsequently boiled in SDS-PAGE sample buffer for 5
`min and further analyzed by SDS-PAGE and Western blotting as described
`Rapamycin Inhibits Constitutive Phosphorylation and Activa-
`above.
`tion of p70s6k in Panc-1 and MiaPaCa-2 Cells. Activation of
`p70s6K and ERK2 Immune Complex Kinase Assays. Serum-starved
`p70s6K by mitogens can be determined by the appearance of slower-
`MiaPaCa-2 and Panc-1 cells were incubated with rapamycin, PD 098059, and
`migrating forms in SDS-PAGE due to the phosphorylation of p70s6K
`TGF-a as indicated in the figure legends. Controls received an equivalent
`amount of solvent. Cells were then lysed at 4°C in 1 ml of lysis buffer.
`on Thr229, Thr389, and Ser404, which are not basally phosphorylated in
`Immunoprecipitations were performed at 4°C using an anti-p70s6K antibody or
`quiescent cells (3). The phosphorylation of these sites can be pre-
`an anti-ERK2 antibody for 2 h, with protein A-agarose added for the second
`vented or reversed by treatment with rapamycin, which specifically
`hour. Immune complexes were washed three times in lysis buffer and once
`inhibits the p70s6K activator FRAP (3, 4). To examine the status of
`with p70s6K kinase buffer [20 mM HEPES (pH 7.4), 10 mM MgCl2, 1 mM DTT,
`p70s6K phosphorylation in human pancreatic cancer cells, cultures of
`and 10 mM b-glycerophosphate] or ERK kinase buffer [15 mM MgCl2, 15 mM
`Panc-1 and MiaPaCa-2 cells were incubated in the absence or pres-
`Tris-HCl (pH 7.4)], respectively. Kinase reactions were performed by re-
`ence of 20 ng/ml rapamycin. Cells were lysed, and the lysates were
`suspending the protein A-Sepharose pellets in 25 ml of kinase assay
`analyzed by immunoblotting. p70s6K exhibited a retarded electro-
`mixture containing the appropriate kinase buffer with 0.2 mM S6 peptide
`phoretic mobility characteristic of the phosphorylated form of this
`(RRRLSSLRA) or myelin basic protein, 20 mM ATP, 5 mCi/ml [g-32P]ATP, 2
`mM cyclic AMP-dependent protein kinase inhibitor peptide, and 100 nM
`enzyme in Panc-1 and MiaPaCa-2 cells. In control experiments, there
`was no retarded electrophoretic mobility of p70s6K in serum-starved
`microcystin LR. Incubations were performed under linear assay conditions at
`30°C for 20 min and terminated by spotting 25 ml of the supernatant onto
`mouse or human fibroblasts (data not shown), in accordance with
`Whatman p81 chromatography paper. Papers were washed four times for 5 min
`previous results (3). Treatment of cells with rapamycin induced a
`in 0.5% o-phosphoric acid, immersed in acetone, and dried before scintillation
`striking dephosphorylation of p70s6K, as demonstrated by the increase
`counting. The average radioactivity of two blank samples containing no
`in the electrophoretic mobility (Fig. 1A, top panels). The effect of
`immune complex was subtracted from the result of each sample.
`rapamycin on constitutive p70s6K phosphorylation was concentration
`DNA Synthesis Assays. MiaPaCa-2 and Panc-1 cells were serum-starved
`dependent; maximum effects were achieved at 6 and 20 ng/ml rapa-
`for 24 h and then incubated with various additions of rapamycin as described
`mycin in Panc-1 and MiaPaCa-2 cells, respectively (Fig. 1A, bottom
`in the figure legends. Control cells received solvent or DMEM/10% FBS to
`panels). Dephosphorylation of p70s6K by rapamycin in Panc-1 and
`determine maximum DNA synthesis. After 18 h of incubation at 37°C,
`MiaPaCa-2 cells was first visible after 5 min and reached a maximum
`[3H]thymidine (0.25 mCi/ml; 1 mM) was added to the cultures, and cells were
`10 min after the addition of rapamycin to the cells (data not shown).
`incubated for another 6 h at 37°C. Cells were then washed with PBS and
`incubated in 5% trichloroacetic acid at 4°C for 30 min, washed with ethanol,
`Next we performed immune complex kinase assays to directly assess
`and solubilized in 1 ml of 2% Na2CO3, 0.1 M NaOH, and 1% SDS. The
`p70s6K activity. Treatment of cells with rapamycin substantially re-
`acid-insoluble radioactivity was determined by Cerenkov counting in 6 ml of
`duced the basal kinase activity of p70s6K by 92% and 99% in serum-
`Ultima Gold (Packard). For detection of BrdUrd incorporation into cellular
`starved Panc-1 and MiaPaCa-2 cells, respectively (Fig. 1B, top pan-
`DNA, MiaPaCa-2 and Panc-1 cells were serum-starved in fresh DMEM for
`els). The effect of rapamycin on p70s6K activity was specific because
`24 h. Cells were then incubated with 20 ng/ml rapamycin or solvent for 24 h
`rapamycin did not affect basal and TGF-a-stimulated activation of the
`at 37°C, with 10 mM BrdUrd added for the last 6 h. Cultures were subsequently
`mitogen-activated protein kinase ERK2 in both cell lines. In contrast,
`washed with PBS, fixed in 70% ethanol for 20 min, and incubated with
`the mitogen-activated protein/ERK kinase 1 inhibitor PD 098059
`anti-BrdUrd monoclonal antibody, followed by labeling with an antimouse
`markedly inhibited basal and TGF-a-stimulated ERK2 activation
`IgG-fluorescein antibody. Cells were examined using a Zeiss Axiophot immu-
`(Fig. 1B, bottom panels).
`nofluorescence microscope. Data are expressed as the percentage of BrdUrd-
`labeled nuclei.
`Effect of Rapamycin on 4E-BP1 Phosphorylation in Panc-1 and
`Growth Assay. Three days after passage, MiaPaCa-2 and Panc-1 cells
`MiaPaCa-2 Cells. It has been suggested that phosphorylation and
`were washed in serum-free DMEM,
`trypsinized, and resuspended in
`thus inactivation of the translation inhibitor 4E-BP1 are also mediated
`DMEM/1% FBS. Cells were plated at a density of 1 3 104 cells in 1 ml of
`by a rapamycin-sensitive pathway (6, 14). Therefore, we examined the
`DMEM/1% FBS in the presence or absence of 20 ng/ml rapamycin in dupli-
`phosphorylation status of 4E-BP1 in serum-starved human pancreatic
`cate. At the times indicated in the figure legends, the cell number was
`cancer cells in the absence or presence of rapamycin. To determine
`determined using a cell counting chamber.
`4E-BP1 phosphorylation, a Western blot analysis was performed
`Clonogenic Assay. MiaPaCa-2 and Panc-1 cells were washed, trypsinized,
`using a polyclonal antibody against 4E-BP1. Three forms of 4E-BP1
`and resuspended in DMEM. The cell number was determined using a cell
`were present in serum-starved Panc-1 and MiaPaCa-2 cells, suggest-
`counting chamber. Cells (3 3 104 ) were mixed with DMEM/1% FBS
`ing constitutive phosphorylation of 4E-BP1 in these cells. Treatment
`containing 0.3% agarose in the presence or absence of rapamycin at the
`concentrations indicated and layered over a solid base of 0.5% agarose in
`with rapamycin leads to a decreased intensity of the upper two bands
`DMEM/1% FBS in the presence or absence of rapamycin at the same con-
`and to an increased intensity of the fastest migrating lower band
`centrations in 33-mm dishes. The cultures were incubated in humidified 5%
`(Fig.1C, left, top and bottom panels). According to previous studies,
`CO2: 95% air at 37°C for 14 days and then stained with the vital stain nitroblue
`the lowest band represents the unphosphorylated form of 4E-BP1 (16,
`tetrazolium. Colonies of .120 mm in diameter (20 cells) were counted using
`17). We next examined whether the constitutive phosphorylation of
`a microscope.
`4E-BP1 was sufficient to decrease the interaction of eIF-4E with
`Materials. Rapamycin was obtained from Calbiochem-Novabiochem. An-
`4E-BP1. Serum-starved Panc-1 cells were incubated with solvent or
`tibodies against p70s6K, 4E-BP1, p27KIP1, cyclin D1, and cyclin E were
`20 ng/ml rapamycin. Cell lysates were immunoprecipitated with a
`obtained from Santa Cruz Biotechnology. The monoclonal anti-eIF-4E anti-
`polyclonal anti-4E-BP1 antibody and analyzed further by Western
`body was from Transduction Laboratories. The NH2-terminally directed anti-
`blotting with a monoclonal anti-eIF-4E antibody. As shown in Fig.1C
`p70s6K polyclonal antibody used to determine p70s6K activity was obtained
`3582
`
`
`
`Downloaded from on June 27, 2015. © 1999 American Association for Cancercancerres.aacrjournals.org
`
`
`Research.
`
`000002
`
`

`

`REGULATION OF CELL GROWTH AND CYCLIN D1 EXPRESSION
`
`Fig. 1. Constitutive phosphorylation/activation of p70s6K and 4E-BP1 in Panc-1 and MiaPaCa-2 cells. A, top panels, serum-starved cultures of Panc-1 (left) and MiaPaCa-2 cells
`(right) were treated with 20 ng/ml rapamycin (Rapa) or received an equivalent amount of solvent (—). p70s6K mobility shift assays were performed as described in “Materials and
`Methods.” The results shown in each case are representative of three independent experiments. The positions of hypophosphorylated p70s6K (p70s6K) and the slower-migrating
`phosphorylated p70s6K (pp70s6K) are indicated by arrows. Bottom panels, serum-starved cultures of Panc-1 (left) and MiaPaCa-2 cells (right) were treated with various concentrations
`of rapamycin as indicated for 20 min or received an equivalent amount of solvent (—). p70s6K mobility shift assays were performed as described in “Materials and Methods.” The results
`shown in each case are representative of three independent experiments. The positions of hypophosphorylated p70s6K (p70s6K) and the slower-migrating phosphorylated p70s6K
`(pp70s6K) are indicated by arrows. B, top panels, serum-starved cultures of Panc-1 (left) and MiaPaCa-2 cells (right) were treated with 20 ng/ml rapamycin for 20 min (Rapa) or received
`an equivalent amount of solvent (—). Cells were subsequently lysed, and immune complex kinase assays for p70s6K activity were performed as described in “Materials and Methods.”
`Bottom panels, serum-starved cultures of Panc-1 (left) and MiaPaCa-2 cells (right) were treated with 20 ng/ml rapamycin (Rapa 1) for 20 min or 20 mM PD 098059 (PD 1) for 40
`min or received an equivalent amount of solvent (—). Cells were then incubated with 50 ng/ml TGF-a for 5 min (TGF-a 1) and lysed, and immune complex kinase assays for ERK2
`activity were performed as described in “Materials and Methods.” C, left panels, serum-starved cultures of Panc-1 (top) and MiaPaCa-2 cells (bottom) were treated with 20 ng/ml
`rapamycin (Rapa) as indicated for 20 min. Control cells received an equivalent amount of solvent (—). 4E-BP1 mobility shift assays were performed as described in “Materials and
`Methods.” The results shown in each case are representative of three independent experiments. The positions of hypophosphorylated 4E-BP1 (4E-BP1) and the slower-migrating
`phosphorylated forms of 4E-BP1 (p4E-BP1) are indicated by arrows. Middle panels, cells were treated as described above and lysed, and lysates were immunoprecipitated using a
`specific anti-4E-BP1 antibody as described in “Materials and Methods.” Western blotting was performed using an anti-eIF-4E antibody (top) or an anti-4E-BP1 antibody (bottom) as
`described in “Materials and Methods.” Right panels, human pancreatic cancer tissue samples were lysed and subsequently analyzed by SDS-PAGE with an anti-p70s6K (top) or an
`anti-4E-BP1 antibody (bottom) as described in “Materials and Methods.” The positions of hypophosphorylated and hyperphosphorylated p70s6K (p70s6K and pp70s6K) and 4E-BP1
`(4E-BP1 and p4E-BP1) are indicated by arrows.
`
`anti-4E-BP1 antibody, similar amounts of 4E-BP1 protein could be
`(middle, top panel), a small amount of eIF4E coimmunoprecipitated
`detected in rapamycin-treated and untreated cells (Fig. 1C, middle,
`with 4E-BP1 in nontreated cells. Upon treatment with rapamycin, the
`bottom panel). In addition, using 7-methyl-GTP-Sepharose that spe-
`amount of eIF-4E that could be detected in 4E-BP1 immunoprecipi-
`cifically binds eIF-4E, an increased amount of 4E-BP1 was found in
`tates increased strikingly. When blots were stripped and reprobed with
`3583
`
`
`
`Downloaded from on June 27, 2015. © 1999 American Association for Cancercancerres.aacrjournals.org
`
`
`Research.
`
`000003
`
`

`

`REGULATION OF CELL GROWTH AND CYCLIN D1 EXPRESSION
`
`Fig. 2. Rapamycin inhibits DNA synthesis in
`Panc-1 and MiaPaCa-2 cells. A, serum-starved cul-
`tures of Panc-1 (left) or MiaPaCa-2 cells (right)
`were washed and incubated at 37°C for 24 h in
`serum-free DMEM containing either 20 ng/ml ra-
`pamycin or an equivalent amount of solvent.
`[3H]Thymidine was added during the last 6 h of the
`incubation, and [3H]thymidine incorporation was
`determined as described in “Materials and Meth-
`ods.” Each point represents the mean of three de-
`terminations and is representative of at least two
`independent experiments. B, serum-starved cultures
`of Panc-1 (left panels) or MiaPaCa-2 cells (right
`panels) were washed and incubated at 37°C for 24 h
`in DMEM containing either 20 ng/ml rapamycin
`(Rapa; bottom panels) or an equivalent amount of
`solvent (—; top panels). BrdUrd was added during
`the last 6 h of theincubation. After 24 h, BrdUrd
`incorporation into cell nuclei was determined as
`described in “Materials and Methods.” Labeled nu-
`clei were visualized by fluorescence microscopy.
`Typical fields are presented. C, BrdUrd incorpora-
`tion was performed as described above for rapamy-
`cin (Rapa 1)-treated or vehicle-treated (—) Panc-1
`(left) or MiaPaCa-2 cells (right). Results are pre-
`sented as the percentage of labeled nuclei and are
`the means of three distinct fields from two separate
`experiments.
`
`active FRAP-p70s6K pathway for pancreatic cancer cell growth. Basal
`7-methyl-GTP-Sepharose immunoprecipitates of lysates of Panc-1
`DNA synthesis in serum-free DMEM as assessed by [3H]thymidine
`cells treated with rapamycin as compared to untreated cells (data not
`shown). Thus, the level of constitutive phosphorylation of 4E-BP1 in
`incorporation was 35% of maximum stimulation in response to 10%
`serum-starved pancreatic cancer cells is sufficient to prevent interac-
`FBS in Panc-1 and MiaPaCa-2 cells (Fig. 2A). Upon treatment with
`rapamycin, basal [3H]thymidine incorporation decreased substantially
`tion with eIF-4E.
`Constitutive p70s6K- and 4E-BP1 phosphorylation was not re-
`in both cell lines. The effect of rapamycin was concentration depend-
`ent, with half-maximal effects at 1 and 3 ng/ml
`in Panc-1 and
`stricted to pancreatic cancer cells exhibiting activating Ki-ras muta-
`MiaPaCa-2 cells, respectively, and maximal effects at 20 ng/ml in
`tions such as MiaPaCa-2 and Panc-1 cells but could also be detected
`both cell
`lines. At
`this concentration, basal DNA synthesis was
`in the human pancreatic cancer cell lines SW 850 and SW 979 that
`reduced by 77% and 66% in Panc-1 and MiaPaCa-2 cells, respectively
`exhibit wild-type Ki-ras (data not shown). Thus, constitutive phos-
`phorylation of p70s6K and 4E-BP1 is not due to the activating Ki-ras
`(Fig. 2A). These results are in good agreement with the data obtained
`on rapamycin-induced dephosphorylation of p70s6K (Fig. 1A). To
`mutation in these cells. Interestingly, constitutive phosphorylation of
`p70s6K and 4E-BP1 could also be observed in a human pancreatic
`further substantiate our observations, we applied a distinct technique
`in which DNA synthesis was determined using an immunofluores-
`carcinoma tissue sample (Fig. 1C, right panels).
`Rapamycin Inhibits DNA Synthesis in Panc-1 and MiaPaCa-2
`cence assay to detect BrdUrd incorporation into cell nuclei. As shown
`Cells. We first examined the effect of rapamycin on basal DNA
`in Fig. 2B, BrdUrd incorporation into cell nuclei was markedly
`inhibited in the presence of rapamycin. At a concentration of 20 ng/ml
`synthesis in both cell lines to determine the role of the constitutively
`3584
`
`
`
`Downloaded from on June 27, 2015. © 1999 American Association for Cancercancerres.aacrjournals.org
`
`
`Research.
`
`000004
`
`

`

`REGULATION OF CELL GROWTH AND CYCLIN D1 EXPRESSION
`
`solid medium in the presence or absence of rapamycin. As shown in
`Fig. 3B, rapamycin markedly inhibited the formation of colonies by
`MiaPaCa-2 and Panc-1 cells in a concentration-dependent manner.
`Half-maximal and maximal effects were achieved at 6 and 20 ng/ml
`rapamycin in both cell lines.
`Rapamycin Inhibits Expression of Cyclin D1 but not Cyclin E
`and p27KIP1. Progression from G1 to the S phase of the cell cycle is
`regulated by the expression of cyclins D and E, which modulate the
`activities of the cyclin-dependent kinases. Rapamycin can block G1 to
`S-phase cell cycle progression in a number of cell types by blocking
`growth factor-stimulated elimination of the cyclin-dependent kinase
`inhibitor p27KIP1 (20, 21). We have recently shown that rapamycin
`strikingly reduces bombesin-induced expression of cyclins D1, D3,
`and E in Swiss 3T3 fibroblasts (22). These effects of rapamycin may
`be a consequence of the inhibition of p70s6K or may be due to a
`distinct pathway(s) regulated by the FRAP-p70s6K pathway. To fur-
`ther explore the nature of the rapamycin-sensitive and -insensitive
`mechanisms regulating the basal growth of human pancreatic cancer
`cells, we determined the expression of cyclin D1, cyclin E, and
`p27KIP1 and correlated these with the activation of p70s6K. As shown
`in Fig. 4, treatment of cells with rapamycin leads to a sustained
`dephosphorylation of p70s6K for up to 36 h. Similar results were
`obtained for 4E-BP1 phosphorylation (data not shown). Rapamycin
`treatment of MiaPaCa-2 cells at a concentration that
`inhibited
`p70s6K2 and 4E-BP1 phosphorylation as well as basal cell growth
`
`Fig. 3. Rapamycin inhibits anchorage-dependent and -independent proliferation of
`Panc-1 and MiaPaCa-2 cells. A, cultures of Panc-1 (left) and MiaPaCa-2 cells (right) were
`incubated at a density of 1 3 104 cells in 1 ml of DMEM containing 1% FBS and 20 ng/ml
`rapamycin (E) or vehicle (F), and cells were counted at day 0, 1, 4, 5, 6, and 7 as
`indicated. Each point represents the mean of two determinations and is representative of
`at least two independent experiments. B, single cell suspensions of Panc-1 (left) or
`MiaPaCa-2 cells (right) were plated at a density of 3 3 104 cells/dish in agarose medium
`containing DMEM/1% FBS and various concentrations of rapamycin as indicated. Col-
`onies were counted after 2 weeks of incubation. In all cases, a representative of two
`independent experiments, each performed in triplicates, is shown.
`
`rapamycin, a maximum 62% reduction in BrdUrd incorporation could
`be detected in both cell lines (Fig. 2C).
`Effect of Rapamycin on Anchorage-dependent and -independ-
`ent Proliferation of Panc-1 and MiaPaCa-2 Cells. Next we exam-
`ined the effect of
`rapamycin on actual cellular proliferation.
`MiaPaCa-2 and Panc-1 cells were incubated in the absence or pres-
`ence of 20 ng/ml rapamycin, and cell numbers were determined over
`a period of up to 7 days. In the presence of rapamycin, cell numbers
`were reduced by a maximum of 66% and 68% at day 7 in Panc-1 and
`MiaPaCa-2 cells, respectively (Fig. 3A). Thus, the constitutively ac-
`tive, rapamycin-sensitive FRAP-p70s6K signaling pathway is likely to
`participate in sustaining anchorage-dependent growth of human
`Panc-1 and MiaPaCa-2 cells. In contrast to recent results obtained in
`rhabdomyosarcoma cells (18), rapamycin did not induce apoptosis in
`pancreatic cancer cells, as judged by an in situ assay to detect DNA
`fragmentation (data not shown).
`Tumors and transformed cells, including human pancreatic cancer
`cells, are able to grow in an anchorage-independent manner by form-
`Fig. 4. Inhibition of cyclin D1 expression by rapamycin in MiaPaCa-2 cells. Subcon-
`fluent cultures of MiaPaCa-2 cells were treated with 20 ng/ml rapamycin for various
`ing colonies in agarose medium. There is even a positive correlation
`times, as indicated. Control cells received an equivalent amount of solvent (—). Cells
`between the cloning efficiency of tumor cells in soft agar and the
`were lysed and further analyzed by Western blotting with either anti-p70s6K antibody,
`anti-cyclin D1 antibody, anti-cyclin E antibody, or anti-p27KIP1 antibody as indicated by
`histological involvement and invasiveness of the tumor in specimens
`an arrow. The results shown in each case are representative of at least three independent
`taken from different carcinomas (19). Consequently, we determined
`experiments. The positions of hypophosphorylated p70s6K (p70s6K) and the slower-
`the ability of MiaPaCa-2 and Panc-1 cells to form colonies in semi-
`migrating phosphorylated p70s6K (pp70s6K) are indicated by arrows.
`3585
`
`
`
`Downloaded from on June 27, 2015. © 1999 American Association for Cancercancerres.aacrjournals.org
`
`
`Research.
`
`000005
`
`

`

`REGULATION OF CELL GROWTH AND CYCLIN D1 EXPRESSION
`
`resulted in a marked and sustained reduction in the expression of
`cyclin D1, compared to the levels observed in cells treated with
`vehicle alone. Reduced cyclin D1 expression was first visible after 6 h
`of incubation and was still detectable after 36 h of incubation with
`rapamycin. In contrast, expression of cyclin E and levels of p27KIP1
`expression did not change in response to rapamycin treatment (Fig. 4).
`Similar data were obtained in Panc-1 cells (data not shown). These
`results suggest that the inhibitory effect of rapamycin on basal pan-
`creatic cancer cell growth is mediated by inhibition of cyclin D1
`expression rather than by inhibition of p27KIP1 elimination.
`
`Discussion
`
`This is the first report demonstrating that the FRAP-p70s6K signal-
`ing pathway is constitutively active in serum-starved human pancre-
`atic cancer cells. The two major downstream targets of FRAP kinase,
`p70s6K and 4E-BP1, were found to be constitutively phosphorylated in
`pancreatic cancer cell lines as well as a human pancreatic cancer
`tissue sample. Activation of both could be prevented by treating cells
`with the selective FRAP inhibitor rapamycin. The effect of rapamycin
`on constitutive p70s6K2 and 4E-BP1 phosphorylation was indeed
`selective, because rapamycin did not prevent basal or TGF-a-induced
`ERK2 activation and hence tyrosine kinase activity of the epidermal
`growth factor receptor, which is required for the activation of ERK2
`by TGF-a. Interestingly, rapamycin substantially inhibited anchorage-
`dependent and -independent growth of MiaPaCa-2 and Panc-1 cells.
`p70s6K mediates 59-terminal oligopyrimidine tract mRNA translation
`(11), and 4E-BP1 is a major regulator of eIF-4E mediated 59 cap
`mRNA translation (12). Thus, these mechanisms are likely to sustain
`protein synthesis and growth in human pancreatic cancer cells. The
`precise contribution of the two FRAP targets to pancreatic cancer cell
`growth is difficult to determine. Recent data suggest that p70s6K and
`4EB-P1 are regulated by FRAP in a parallel rather than sequential
`manner (14). Furthermore, 4E-BP1 obviously plays an independent
`role in the rapamycin-sensitive regulation of cell growth: rapamycin
`can still prevent 4E-BP1 phosphorylation and cell growth in
`p70s6K2/2 cells (15). The antiproliferative effect of rapamycin in
`p70s6K2/2 cells could possibly be due to the inhibition of a novel,
`rapamycin-sensitive p70s6K isoform, which has recently been de-
`scribed in these cells (23). However, dephosphorylated 4E-BP1 has
`clearly been demonstrated to inhibit cell growth (13). Thus, constitu-
`tively phosphorylated p70s6K and 4EB-P1 are likely to contribute to
`both anchorage-dependent and -independent growth of human pan-
`creatic cancer cells. Rapamycin also blocks constitutive p70s6K phos-
`phorylation and proliferation in classical small cell lung cancer cells
`(10). Therefore,
`if cancer cells exhibit constitutive activation of
`FRAP/p70s6K, this signaling pathway is likely to play a role in the
`autonomous growth of these tumors.
`Because p70s6K regulates progression from G1 to the S phase of the
`cell cycle, we reasoned that the molecular mechanism underlying
`growth inhibition by rapamycin could be related, at least in part, to the
`cell cycle machinery.
`Indeed, the inhibitory effect of rapamycin on pancreatic cancer
`cell growth was associated with a reduction in cyclin D1 expres-
`sion. This was not due to a general inhibition of protein synthesis
`by rapamycin because we could not detect any change in the
`expression of cyclin E or p27KIP1. It
`is presently not known
`whether the effects of rapamycin on p70s6K phosphorylation/acti-
`vation, 4E-BP1 phosphorylation, and cyclin D1 expression in
`human pancreatic cancer cells are mediated by a linear, split, or
`parallel pathway(s). However, because cyclin D1 expression is
`rapamycin-sensitive in human pancreatic cancer cells, its regula-
`tion is likely to involve a FRAP-dependent pathway including the
`3586
`
`activation of p70s6K and the phosphorylation of 4E-BP1. This

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket